RNA 5‐Methylcytosine ( m5C ) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation
WIREs RNA · 2026-11 · 17 (6)
DOI: 10.1002/wrna.70067 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift WIREs RNA, online erschienen am 08.11.2026. Verfasst von Jie Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China. Hauptthemen laut MEDLINE: 5-Methylcytosine, Neoplasms, Drug Resistance, Neoplasm. Die Arbeit nennt 176 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Xinjiang Province of China, 789 Young Scientific and Technological Talent Development Program.
Abstract (Originalsprache)
RNA 5‐methylcytosine (m5C) has emerged as an important epitranscriptomic modification in cancer. Rather than acting as a uniformly oncogenic mark, m5C produces context‐dependent effects by coupling RNA fate to cellular adaptation. Through control of RNA stability, nuclear export, translation, splicing, and RNA structure, the m5C machinery connects therapeutic stress to DNA damage repair, redox homeostasis, metabolic plasticity, cancer stemness, and tumor–immune interactions. Here, we synthesize the molecular basis of and detection of RNA m5C, distinguish causal from associative evidence, and examine how m5C‐dependent RNA regulation contributes to tumor progression and resistance to chemotherapy, radiotherapy, targeted therapy, and immunotherapy responses. We also discuss tumor‐suppressive and context‐dependent activities of individual NSUN proteins, cross‐talk with other epigenetic and epitranscriptomic pathways, and the methodological limitations that complicate m5C mapping. Current m5C‐directed compounds remain preclinical; therefore, their most immediate value lies in mechanistic validation and biomarker development rather than established clinical use. A rigorous, method‐aware framework will be essential for determining when m5C is a driver, a permissive adaptation, or a correlate of therapeutic resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Research Institute, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
- NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, Chin…
- Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China.
- Department of Head and Neck Surgery, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
- Oncology Department, Xiangya Hospital Central South University, Changsha, Hunan, China.
- Furong Laboratory, Changsha, Hunan, China.
ORCID-Profile: Wei Xiong, WenJia Guo, Zhaoyang Zeng
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Xinjiang Province of China
- 789 Young Scientific and Technological Talent Development Program
- Xinjiang Medical University Scientific Research Innovation Team Project
- Xinjiang Uygur Autonomous Region Key R&D Program Special Project
- Fundamental Research Funds for Central Universities of the Central South University
Zitieren
APA
Wu, J., Wang, X., Ge, J., Lin, J., Pan, G., Mendoza, J. J., Wu, Y., Xiong, W., Guo, W., & Zeng, Z. (2026). RNA 5‐Methylcytosine ( m5C ) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation. WIREs RNA, 17(6). https://doi.org/10.1002/wrna.70067
Vancouver
Wu J, Wang X, Ge J, Lin J, Pan G, Mendoza JJ, et al. RNA 5‐Methylcytosine ( m5C ) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation. WIREs RNA. 2026;17(6). doi:10.1002/wrna.70067
BibTeX
@article{Wu2026,
author = {Wu, Jie and Wang, XiaoGang and Ge, JunShang and Lin, Jing and Pan, GuangPeng and Mendoza, Juana Jessica and Wu, Yunhan and Xiong, Wei and Guo, WenJia and Zeng, Zhaoyang},
title = {RNA 5‐Methylcytosine ( m5C ) in Cancer: An Emerging Epitranscriptomic Hub for Therapy Resistance and Clinical Translation},
journal = {WIREs RNA},
year = {2026},
volume = {17},
number = {6},
doi = {10.1002/wrna.70067}
}
EUVIMED